Inhibition of G-Protein-Activated Inwardly Rectifying K+ Channels by the Selective Norepinephrine Reuptake Inhibitors Atomoxetine and Reboxetine
Authors:
- 10 March 2010
- journal article
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 35 (7) , 1560-1569
Abstract
Atomoxetine and reboxetine are commonly used as selective norepinephrine reuptake inhibitors (NRIs) for the treatment of attention-deficit/hyperactivity disorder and depression, respectively. Furthermore, recent studies have suggested that NRIs may be useful for the treatment of several other psychiatric disorders. However, the molecular mechanisms underlying the various effects of NRIs have not yet been sufficiently clarified. G-protein-activated inwardly rectifying K+ (GIRK or Kir3) channels have an important function in regulating neuronal excitability and heart rate, and GIRK channel modulation has been suggested to be a potential treatment for several neuropsychiatric disorders and cardiac arrhythmias. In this study, we investigated the effects of atomoxetine and reboxetine on GIRK channels using the Xenopus oocyte expression assay. In oocytes injected with mRNA for GIRK1/GIRK2, GIRK2, or GIRK1/GIRK4 subunits, extracellular application of atomoxetine or reboxetine reversibly reduced GIRK currents. The inhibitory effects were concentration-dependent, but voltage-independent, and time-independent during each voltage pulse. However, Kir1.1 and Kir2.1 channels were insensitive to atomoxetine and reboxetine. Atomoxetine and reboxetine also inhibited GIRK currents induced by activation of cloned A1 adenosine receptors or by intracellularly applied GTPγS, a nonhydrolyzable GTP analogue. Furthermore, the GIRK currents induced by ethanol were concentration-dependently inhibited by extracellularly applied atomoxetine but not by intracellularly applied atomoxetine. The present results suggest that atomoxetine and reboxetine inhibit brain- and cardiac-type GIRK channels, revealing a novel characteristic of clinically used NRIs. GIRK channel inhibition may contribute to some of the therapeutic effects of NRIs and adverse side effects related to nervous system and heart function.Keywords
This publication has 63 references indexed in Scilit:
- Selective noradrenaline reuptake inhibitor atomoxetine directly blocks hERG currentsBritish Journal of Pharmacology, 2009
- Atomoxetine for treatment of marijuana dependence: A report on the efficacy and high incidence of gastrointestinal adverse events in a pilot studyDrug and Alcohol Dependence, 2008
- Evaluation of radioiodinated (2S,αS)-2-(α-(2-iodophenoxy)benzyl)morpholine as a radioligand for imaging of norepinephrine transporter in the heartNuclear Medicine and Biology, 2008
- The Effects of Chronic Norepinephrine Transporter Inactivation on Seizure Susceptibility in MiceNeuropsychopharmacology, 2005
- Atomoxetine hydrochlorideNature Reviews Drug Discovery, 2004
- Seizures and Prolonged QTc With Atomoxetine OverdoseAmerican Journal of Psychiatry, 2004
- Evaluation of radioiodinated (R)-N-methyl-3-(2-iodophenoxy)-3-phenylpropanamine as a ligand for brain norepinephrine transporter imagingNuclear Medicine and Biology, 2004
- AtomoxetineDrugs, 2004
- Molecular Cloning of a Mouse G-Protein-Activated K+ Channel (mGIRK1) and Distinct Distributions of 3 GIRK (GIRK1, 2 and 3) mRNAs in Mouse BrainBiochemical and Biophysical Research Communications, 1995
- Cloning and expression of an inwardly rectifying ATP-regulated potassium channelNature, 1993